Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs iShares US Power Infrastructure ETF (POWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs iShares US Power Infrastructure ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while iShares US Power Infrastructure ETF trades at $24.99 (market cap $448.01M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.2× iShares US Power Infrastructure ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and iShares US Power Infrastructure ETF for 19 Days on average.
| MRVI | POWR | |
|---|---|---|
Market Cap | $972.90M | $448.01M |
Volume | 4,325,710 | 115,109 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $28.22 |
52-Week Low | $2.83 | $23.20 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About iShares US Power Infrastructure ETF
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →
